. Author manuscript; available in PMC: 2020 Dec 4.

Published in final edited form as: JAMA Cardiol. 2020 Feb 1;5(2):147–155. doi: 10.1001/jamacardio.2019.4528

Table 3.

Association Between CPC Counts and Risk of Cardiovascular Death and Myocardial Infarction^a

	Hazard Ratio (95% CI)
Variable	Model 1^b	Model 2 (CD34⁺)^c	Model 3 (CD34⁺/CXCR4⁺)^d
Baseline CPC Count^e
CD34⁺	1.26 (1.10–2.10)	1.18 (0.91–2.14)	NA
CD34⁺/CXCR4⁺	1.48 (1.23–2.95)	NA	1.17 (0.80–2.02)
Poststress CPC Count^e
CD34⁺	1.64 (1.11–2.43)	1.58 (1.09–2.34)	NA
CD34⁺/CXCR4⁺	1.84 (1.34–3.12)	NA	1.77 (1.22–2.98)
Change in CPC Count^e
CD34⁺	2.12 (1.25–3.52)	1.98 (1.16–3.24)	NA
CD34⁺/CXCR4⁺	2.70 (1.06–7.12)	NA	2.65 (1.06–6.54)

Abbreviations: CPC, circulating progenitor cell; NA, not applicable.

Data were derived using Cox regression analysis.

Model 1 was adjusted for baseline demographics (age, sex, race, smoking history, body mass index [calculated as weight in kilograms divided by height in meters squared]) and cardiovascular risk factors (history of heart failure, hypertension, dyslipidemia, and diabetes).

Model 2 was adjusted for all variables in model 1 plus the presence of myocardial ischemia and the baseline CD34⁺ count.

Model 3 was adjusted for all variables in model 1 plus the presence of myocardial ischemia and the baseline CD34⁺/CXCR4⁺ count.

Per 50% decrease.